Should Adults 50 And Older Wait For A New MRNA Flu Shot This Fall?

If you are 50 or older, the safest default plan is still the usual one: do not delay your fall flu shot just because a new mRNA flu vaccine may become available. On June 18, 2026, an FDA advisory committee voted that Moderna’s mFlusiva appears to have benefits that outweigh risks for adults 50 to 64 and for adults 65 and older. But an advisory vote is not the same as FDA approval, and the final agency decision is still pending.

For everyday readers, that distinction matters more than the headline. CDC still recommends a flu vaccine every season for everyone 6 months and older, and September or October is generally a good time for most adults who need one dose. In other words, people should not assume they need to hold off on routine flu vaccination while waiting for one specific product.

What happened on June 18, 2026

The June 18 meeting was a review by outside FDA advisers, not a product launch. According to FDA briefing materials, Moderna is seeking traditional approval for adults ages 50 through 64 and accelerated approval for adults 65 and older, with additional follow-up planned for the older group. Associated Press reported that the FDA is expected to make a final decision in early August 2026, ahead of the 2026-27 flu season.

What the trial results suggest so far

The main phase 3 study included more than 40,000 adults ages 50 and older. FDA reviewers reported that mFlusiva showed better relative protection than a licensed standard-dose comparator, with relative vaccine efficacy of 26.6% against RT-PCR-confirmed, protocol-defined influenza-like illness over about six months of follow-up. The peer-reviewed New England Journal of Medicine report supports the overall finding that the vaccine performed better than standard-dose licensed flu vaccines in this study population.

That is encouraging, but it does not settle every practical question for older adults. The study compared the mRNA shot with standard-dose flu vaccines, not with the higher-dose, adjuvanted, or recombinant flu vaccines that are already commonly favored for many adults 65 and older. So the trial does not answer whether the new shot would be better than the senior-preferred options people may already be offered this fall.

What the safety review found

FDA reviewers said short-term reactions were more common with the mRNA vaccine than with comparator shots. Local reactions and systemic symptoms such as fatigue, headache, fever, chills, and muscle aches were reported more often. At the same time, the FDA’s integrated safety summary found that serious adverse events, deaths, and adverse events of special interest were generally balanced between groups.

Important limits remain. FDA reviewers highlighted single-season follow-up, no data in immunocompromised people, limited data in very frail older adults, and limited information on giving this vaccine at the same visit as other routine shots. For adults 65 and older, the FDA review also said post-approval work would be needed to confirm clinical benefit.

What CDC still advises right now

CDC’s current advice has not changed: get vaccinated every year, ideally by the end of October, and do not skip vaccination just because one specific product is unavailable. For adults 65 and older, current U.S. guidance gives preference to high-dose, adjuvanted, or recombinant flu vaccines when available. If one of those is not available at the time of vaccination, CDC says people in that age group should still get another age-appropriate flu vaccine rather than go unvaccinated. AAFP’s adult immunization schedule overview reflects the same general approach.

So should you wait?

For most adults 50 and older, probably not. If mFlusiva is approved and available by the time you are ready for your flu shot, it may become another option to discuss. But as of June 28, 2026, the evidence does not support postponing an on-time flu vaccine just to see whether this product reaches the market.

This is not the same as saying the new vaccine looks ineffective or unsafe. The narrower point is that it remains pending, its biggest trial was not a head-to-head test against the senior-preferred flu shots many older adults already receive, and CDC’s public guidance still supports getting seasonal flu protection on the usual fall schedule.

Who may want a more individualized conversation

Some people may want to slow down and ask more questions before choosing a product. That includes very frail older adults, immunocompromised people, and caregivers helping make decisions for someone with multiple medical conditions. Those are the groups where the FDA review found thinner evidence so far, so a clinician may help weigh timing, availability, and which current vaccine option makes the most sense.

What readers can do now

Plan for your usual fall flu-shot window, which CDC generally places in September or October for adults who need one dose.
If you will be 65 or older this season, ask which of the currently preferred flu-vaccine options is likely to be available where you get vaccinated.
If you are frail, immunocompromised, or helping manage care for an older family member, ask a clinician whether it makes sense to use a routine available option or wait briefly for more clarity after the FDA’s final decision.
Watch for the FDA’s final decision in early August 2026 and for any later CDC or clinician-group guidance if mFlusiva is cleared.

The bottom line: the new mRNA flu shot looks promising, but it is still pending at the FDA. For most adults 50 and older, the practical plan remains the same: get an age-appropriate flu vaccine on the usual fall schedule instead of waiting and risking a missed opportunity.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.